A Phase 3 interventional study of QL1206 and Prolia® in Postmenopausal Women With Osteoporosis at High Risk of Fracture, sponsored by Qilu Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to female participants aged 50 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-07-14.
Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 87 studies in Osteoporosis with a site in China — 27 open to participants now, 33 under way, 3 of them phase 3. Osteoporosis · China.
Among the 87 studies in Osteoporosis with a site in China, this one is the 15th largest by planned enrollment of the 57 interventional ones that give a count, is one of 11 that started in 2025, is one of 11 in phase 3, reaches primary completion later than 24 of the 32 other live ones, and was the 74th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →27 of the 87 studies in Osteoporosis with a site in China are open now. Recruiting first, the newest first:
Shenzhen Salubris Pharmaceuticals Co., Ltd. · Sites in China
Ages 45–80 · Women only
Dr. Li Chen · Sites in China
Ages 18+ · Healthy volunteers
Peking University People's Hospital · Sites in China
Ages 18+ · Healthy volunteers
Wuhan Union Hospital, China · Sites in China
Ages 40+
Third Affiliated Hospital, Sun Yat-Sen University · Sites in China
Ages 50+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 50 Years to 85 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
87 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 11 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 278 is above the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 120 across the 57 interventional studies, 1,750 across the 30 observational. Of the 33 that completed or were terminated, 6 (18%) have results posted.
This tab as a report to print or save as PDF → With an account.
22 of 87 have an industry lead sponsor. The 10 most frequent:
Qilu Pharmaceutical Co., Ltd. is the lead sponsor of 200 studies on the registry; 122 are open to participants now.
Qilu Pharmaceutical Co., Ltd. has 2 studies filed under Osteoporosis — fewer than ten, so there is no comparison to draw.
11 of the studies in Osteoporosis with a site in China that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062978Phase 3Qilu Pharmaceutical Co., Ltd.A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | 2027-01 |
| NCT07895082Phase 3Shanghai University of Traditional Chinese MedicineQuanduzhong Capsules for Primary Osteoporosis | 2027-04-15 |
| NCT07474571Peking University People's HospitalEvaluation of Musculoskeletal Aging and Related Disorders Via Advanced Clinical Imaging | 2026-12-01 |
| NCT07165158The First Affiliated Hospital of Xiamen UniversityThe Effect of Semaglutide on Bone Health | 2026-12-31 |
| NCT06379243The Seventh Affiliated Hospital of Sun Yat-sen UniversityDevelopment and Validation of a Postoperative Re-fracture Risk Model for Osteoporotic Spinal Fractures | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 87 studies in Osteoporosis with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a multicenter, randomized, double-blind comparative study to valuating the efficacy and safety of QL1206 and Prolia® in postmenopausal women with osteoporosis at high risk of fracture.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QL1206 Denosumab injection(60 mg)
Drug: QL1206
Prolia® Denosumab injection(60 mg)
Drug: Prolia®
QL1206 Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
Prolia® Denosumab injection(60 mg) was administered subcutaneously once every 6 months for a maximum of 2 consecutive doses throughout the trial.
Percent Change From Baseline in lumbar spine(LS)-BMD at Month 12
Percent Change From Baseline in lumbar spine(LS)-BMD at Month 12
Time frame: Baseline and 12 months
Started Jun 2025 (actual). Primary completion is estimated for Jan 2027, 19 months after the start.
Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's planned 19 months is below that.
Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: QL1206
Qilu Pharmaceutical Co., Ltd. →